Skip to main content

Generics

  • Allergan settles Restasis suit, grants authorized generic to Family Care

    DUBLIN — Allergan and its subsidiaries on Monday announced that it has reached a settlement regarding its litigation with Famy Care Limited relating to Allergan's Restasis (cyclosporine ophthalmic emulsion) 0.05%.

    The patents relative to Restasis are listed in the Orange Book and expire on Aug. 27, 2024, Allergan stated.

  • FDA approves Humira-biosimilar Cyltezo

    SILVER SPRING, Md. — The Food and Drug Administration last week approved Boehringer Ingelheim's Cyltezo (adalimumab-adbm) subcutaneous injection, a new biosimilar to AbbVie's Humira (adalimumab).

  • Antitrust suit involving generic Lipitor, Effexor XR back on

    A United States appeals court has revived an antitrust lawsuit against four drug makers, alleging that they hamstrung generics for Lipitor and Effexor XR.

    The plaintiffs, a coalition of labor unions and retailers, including Rite Aid and Walgreens, accused four drug makers of reverse settlement payment deals, in which a drug’s patent holder pays the accused infringer not to produce the patented item. The plaintiffs allege Ranbaxy accepted such payments from Pfizer to delay generics for Lipitor, while Wyeth accepted payments from Teva to delay Effexor XR.

  • FDA approves Solco Healthcare’s Cymbalta generic

    SILVER SPRING, Md. — The Food and Drug Administration has approved Solco Healthcare’s generic of Cymbalta (duloxetine) delayed-release capsules, the company recently announced.

    The drug is indicated to treat major depressive disorder in adults, as well as general anxiety disorder in adults and children ages 7 years and older. It also can be used to treat fibromyalgia or chronic muscle or joint pain.

  • Amneal launches generic form of Tamiflu

    BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched oseltamivir phosphate capsules, USP, in three strengths: 30-mg, 45-mg and 75-mg. The Amneal generic is an AB-rated therapeutic equivalent to Tamiflu. Each strength is available in 10-count blister dose-packs.

    “Flu season is closer than we realize,” said Jim Luce, Amneal EVP, sales and marketing. “Amneal strives to assist healthcare providers and their patients by providing more affordable and greater access to treatment with our generic medication.”

  • Camber names Walgreens trading partner of the year

    Camber Pharmaceuticals on Monday awarded Walgreens Boots Alliance in recognition of its status as the No. 1 trading partner for 2016-2017. On hand for the presentation were Stu Messinger of Camber Pharmaceuticals; Sarah Evans of Walgreens Boots Alliance; Kon Ostaficiuk of Camber Pharmaceuticals; Mike Allen of Walgreens Boots Alliance; Pete Romer of Camber Pharmaceuticals; and Brian Schneider of Walgreens Boots Alliance.

     

  • As generics savings increase, FDA looks to spark competition

    Generic medications made up 89% of dispensed U.S. prescriptions in 2016, but only 26% of total drug costs. The use of generics brought savings of $253 billion in 2016, bringing the 10-year savings from generics to $1.67 trillion, according to the ninth annual “Generic Access and Savings in the U.S.” report compiled by the QuintilesIMS Institute for the Association for Accessible Medicines (formerly the Generic Pharmaceutical Association).

  • Teva intros generic Axiron in the U.S.

    JERUSALEM — Teva late last week announced the launch of generic Axiron (testosterone) topical solution CIII, 30-mg-1.5-mL, in the United States.

    Testosterone topical solution CIII is a prescription medicine used to treat adult males who have low or no testosterone due to certain medical conditions. It is supplied in a metered dose pump with an underarm applicator.

    Axiron had annual sales of approximately $247 million in the U.S., according to IMS data as of May 2017.

     

X
This ad will auto-close in 10 seconds